These approaches significantly increase the sensitivity of tumor cells to the immune system by inhibiting the activity of AIM2 or inflammasomes, or by promoting the oncolytic effects of AIM2, thereby augmenting the anti-tumor immune response (Figure 5). Here, AIM2 is linked to neoplasm.